TIRZEPATIDE

Brand name:

• Mounjaro®

Pharmaceutical company:

ELI LILLY AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Type 2 Diabetes Mellitus (T2D)

PBAC Submission type:

New listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2023

Related medicines:

--

Submission received for:

July 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 05/07/2023

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---